NEW BRUNSWICK, N.J.,
May 20, 2015 /PRNewswire/ -- At
a meeting today with industry analysts, senior leaders from the
Janssen Pharmaceutical Companies of Johnson &
Johnson (Janssen) will announce plans to file for regulatory
approval of more than 10 new products between 2015 and 2019, each
with the potential to exceed $1
billion in revenue1, as well as more than 40 line
extensions of existing and new medicines.
With a portfolio focused on five core therapeutic areas –
Immunology, Infectious Diseases & Vaccines, Neuroscience,
Cardiovascular & Metabolism and Oncology – the Pharmaceutical
segment of Johnson & Johnson (NYSE: JNJ) is delivering
transformational new medicines for unmet medical needs
worldwide. Janssen has launched 14 new products since 2009,
seven of which already exceed or are on track to achieve sales in
excess of $1 billion during
2015.2 These new products, coupled with core growth
brands, have fueled industry-leading sales growth and contributed
significantly to the earnings growth of Johnson & Johnson. The
combined strength of Janssen's in-market portfolio and robust
near-term pipeline provides the momentum to sustain above-industry
compound annual growth through 2019.
"In the past two years, our performance and growth rates have
been industry-leading, and we look forward to continuing to drive
above-industry growth with our current in-market portfolio and next
wave of medicines," said Joaquin
Duato, Worldwide Chairman, Pharmaceuticals, Johnson &
Johnson. "We are working with our partners to advance the
innovative products in our pipeline and to deliver significant
benefits to patients."
The total pharmaceutical market reached $1 trillion in 2014 with nearly 40 percent of the
growth coming from specialty medicines, including oncology,
autoimmune, respiratory and anti-viral medications. Going forward,
the total global branded pharmaceuticals market is expected to grow
at a compound annual operational growth rate of approximately 3
percent from 2014 to 2019, according to IMS Health, the independent
analysis and market research service that tracks the industry.
Among the top 10 global pharmaceutical companies, IMS Health also
reports that the Pharmaceutical segment of Johnson & Johnson
was among the fastest growing in the U.S., Europe and Japan in 2014, with sales of $32.3 billion, representing an operational
increase of 16.5 percent3 versus 2013.
"Our innovation strategy has delivered transformational products
for patients and also created a cycle of success that positions us
for continued growth across the entire Johnson & Johnson
enterprise," said Paul Stoffels,
M.D., Chief Scientific Officer and Worldwide Chairman,
Pharmaceuticals, Johnson & Johnson. "With a single-minded focus
on unmet medical need and true differentiation, we've built an
industry-leading pipeline to improve and extend people's lives and
also create value for society and our business."
Late-stage products expected to drive growth in the next several
years, following regulatory approvals, include daratumumab for
multiple myeloma; sirukumab for rheumatoid arthritis; guselkumab
for psoriasis; JNJ-927 (ARN-509) for pre-metastatic prostate
cancer; imetelstat for myelofibrosis; JNJ-493 (FGFRi kinase
inhibitor) for urothelial cancer; esketamine for
treatment-resistant depression; AL-8176 for respiratory syncytial
virus (RSV); fulranumab for osteoarthritic pain; JNJ-872 (VX-787)
for influenza A; JNJ-922 (Orexin-2 antagonist) for primary
insomnia; and AL-335 for hepatitis C.4 In addition,
daratumumab and esketamine have both received Breakthrough Therapy
Designations from the U.S. Food and Drug Administration
(FDA). Janssen is also announcing today that it plans to
submit a Biologic Licensing Application to the FDA and a Marketing
Authorization Application to the EMA this year for daratumumab in
double refractory multiple myeloma. The submission will be based on
Phase 2 data, which will be presented at the upcoming American
Society of Clinical Oncology (ASCO) meeting.
"Our innovation model and capital allocation framework provide
us the flexibility to source both internal and external innovations
to create an industry-leading portfolio that is advancing our
vision of a world without disease," said Dominic J. Caruso, Vice President, Finance and
Chief Financial Officer, Johnson & Johnson.
In February 2015, Janssen
announced the launch of three new research platforms focused on
disease prevention, disease interception, and the microbiome, to
underpin ongoing research and propel scientific knowledge in these
areas of significant potential to change the way diseases are
managed. The Janssen Prevention Center focuses on prevention of
chronic, non-communicable diseases; the Disease Interception
Accelerator is focused on tackling the origins of disease and
intercepting progression to disease for people at-risk – before
they get sick; and the Janssen Human Microbiome Institute focuses
on the diverse population of bacteria living in and on the human
body to develop therapeutic targets and diagnostic capabilities
that have the potential to transform human health.
"The future of health care lies in not only treating disease but
also preventing and intercepting diseases before illness occurs,"
said William N. Hait, M.D., Ph.D.,
Global Head of Janssen Research & Development. "Using our
powerful research platforms in combination with our five focused
therapeutic areas, underpinned by strong in-house capabilities and
cutting-edge external partnerships, we are striving to deliver the
next generation of medical innovations that prevent, intercept and
treat disease."
About Today's Meeting
The meeting will be webcast starting at 8:30 a.m. today and can be accessed along with
full copies of the presentations and speaker biographies via the
Johnson & Johnson Investor Relations website:
www.investor.jnj.com. A replay and podcast will be available
approximately two hours after the live webcast. A live Twitter feed
for today's meeting is accessible via #JNJPharm15.
Users of the Johnson & Johnson Investor Relations mobile app
for the iPad® and iPhone® mobile digital
devices can also access the event. This free app is available in
the iTunes® store and includes stock information, news
releases, company information, webcasts, SEC filings, the company's
pharmaceutical product pipeline and Annual Reports, among other
information.
About Johnson & Johnson
Caring for the world, one person at a time…inspires and unites
the people of Johnson & Johnson. We embrace research and
science – bringing innovative ideas, products and services to
advance the health and well-being of people. Our approximately
127,000 employees at more than 265 Johnson & Johnson operating
companies work with partners in health care to touch the lives of
over a billion people every day, throughout the world.
Cautions Concerning Forward-Looking Statements
This press release contains "forward-looking statements" as
defined in the Private Securities Litigation Reform Act of 1995
regarding, among other things, future operating and financial
performance and product development. The reader is cautioned not to
rely on these forward-looking statements. These statements are
based on current expectations of future events. If underlying
assumptions prove inaccurate or known or unknown risks or
uncertainties materialize, actual results could vary materially
from the expectations and projections of the Janssen Pharmaceutical
Companies and/or Johnson & Johnson. Risks and uncertainties
include, but are not limited to: challenges and uncertainties
inherent in new product development, including uncertainty of
clinical success and decisions of regulatory authorities regarding
approval, labeling and other matters that could affect the
availability or commercial potential of product candidates;
uncertainty of commercial success for new and existing products;
the ability of the company to successfully execute strategic plans;
challenges to patents; the impact of patent expirations; impact of
business combinations and divestitures; competition, including
technological advances, new products and patents attained by
competitors; future clinical data and analysis, including post
marketing surveillance; economic factors, such as interest rate and
currency exchange rate fluctuations; changes to applicable laws and
regulations, including global health care reforms; trends toward
health care cost containment; changes in behavior and spending
patterns or financial distress of purchasers of health care
products and services; product efficacy or safety concerns
resulting in product recalls or regulatory action; and increased
scrutiny of the health care industry by government agencies. A
further list and description of these risks, uncertainties and
other factors can be found in Johnson & Johnson's Annual Report
on Form 10-K for the fiscal year ended December 28, 2014, including Exhibit 99 thereto,
and the company's subsequent filings with the Securities and
Exchange Commission. Copies of these filings are available online
at www.sec.gov, www.investor.jnj.com, or on request from Johnson
& Johnson. Any forward-looking statement made in this release
speaks only as of the date of this release. The Janssen
Pharmaceutical Companies and Johnson & Johnson do not undertake
to update any forward-looking statements as a result of new
information or future events or developments.
iPad, iPhone and iTunes are trademarks of Apple Inc.
1 Peak non-adjusted sales, including partner sales,
where applicable.
2 Includes partner sales, where applicable.
3 Operational growth excludes the effect of
translational currency; total reported growth was 14.9 percent.
4 Many of these products were developed in
collaboration with strategic partners or are licensed from other
companies; see webcast presentation for more information.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/johnson--johnson-pharmaceutical-segment-to-continue-driving-above-industry-growth-with-plans-to-file-more-than-10-new-products-by-2019-each-with-potential-to-exceed-1-billion-in-revenue-300086229.html
SOURCE Johnson & Johnson